Long intergenic non-coding RNA APOC1P1-3 inhibits apoptosis by decreasing α-tubulin acetylation in breast cancer

X-H Liao1,6, J-G Wang2,6, L-Y Li1, D-M Zhou2, K-H Ren2, Y-T Jin3, L Lv1, J-G Yu1, J-Y Yang1, Q Lu1, Q Zou3, J Yu4, X-P Liu*2,5 and P Zhou*1

Increasing evidence indicates that long non-coding RNAs (lncRNAs) act as important regulatory factors in tumor progression. However, their roles in breast cancer remain largely unknown. In present studies, we identified aberrantly expressed long intergenic non-coding RNA APOC1P1-3 (lincRNA-APOC1P1-3) in breast cancer by microarray, verified it by quantitative real-time PCR, and assessed methylation status in the promoter region by pyrosequencing. We also investigated the biological functions with plasmid transfection and siRNA silencing experiments, and further explored their mechanisms by RNA pull-down and RNA immunoprecipitation to identify binding proteins. We found that 224 lncRNAs were upregulated in breast cancer, whereas 324 were downregulated. The lincRNA-APOC1P1-3 was overexpressed in breast cancer, which was related to tumor size and hypomethylation in its promoter region. We also found that APOC1P1-3 could directly bind to tubulin to decrease α-tubulin acetylation, to inactivate caspase-3, and to inhibit apoptosis. This study demonstrates that overexpression of APOC1P1-3 can inhibit breast cancer apoptosis.

Cell Death and Disease (2016) 7, e2236; doi:10.1038/cddis.2016.142; published online 26 May 2016

Long non-coding RNAs (lncRNAs) are a group of non-protein-coding transcripts longer than 200 nucleotides. They are found in sense or antisense orientation to protein-coding genes, within introns of protein-coding genes or in intergenic regions of the genome. Although significant numbers of lncRNAs have been identified, most of them remain largely uncharacterized and little is known about their functions.1 There are reports that they not only interact directly with DNA, mRNAs or proteins (such as transcription factors), but also with other regulatory non-coding RNAs.2 By binding to regulatory components and forming lncRNA–gene complexes, they cause genetic regulations or epigenetic modifications.3

Recently, lncRNAs draw attention on their potential contribution towards disease etiology. Accumulating findings implicate that lncRNAs are expressed aberrantly in the cancer development process, including proliferation, metastasis, and apoptosis. For example, lincRNA-GAS5 expression is significantly downregulated in breast cancer cells, promoting apoptosis.4 The long intergenic non-coding RNA (lincRNA) p21, which contains p53-binding sites for activation during DNA damage, is regarded as an important repressor in the p53-mediated pathway and apoptosis.5 The lncRNAs involved in breast carcinogenesis are still in need of further exploring.

Apolipoprotein C-I pseudogene 1 (APOC1P1) is a pseudogene located in 19q13.2 between apolipoprotein C-I and apolipoprotein C-IV. It encodes three RNA transcript variants that belong to lincRNA family. The variant 3 (lincRNA-APOC1P1-3), which is shorter than the variant 1 and 2, lacks an alternate internal segment and uses an alternate internal splice site. Its expression and function in human diseases are unknown. In present studies, we tested the hypothesis that APOC1P1-3 overexpression involved in breast cancer progression. Using the microarray, we confirmed that lincRNA-APOC1P1-3 is highly expressed in breast cancer tissues. Microarray results were validated with quantitative real-time PCR in breast cancer cell lines and tissues. Biological functions of lincRNA-APOC1P1-3 were assessed by gain versus loss function studies and regulatory mechanisms were investigated by RNA pull-down, RNA immunoprecipitation (RIP), and pyrosequencing. Our data support this hypothesis.

Results

LincRNA-APOC1P1-3 is overexpressed in breast cancers. Our microarray results (NCBI GEO accession: GSE80266) showed that 224 lncRNAs increased and 324
Figure 1  LncRNA microarray screening and qPCR validation for differentially expressed lncRNAs in breast cancer. The microarray results in five pairs of fresh breast cancer tissues and corresponding para-cancer normal tissues were shown in (a, b, and c). (a) Quality assessment of lncRNA data after filtering using box plot. The box plot is a convenient way to quickly visualize the distributions of a data set. It is commonly used for comparing the distributions of the intensities from all samples. After normalization, the distributions of log2 ratios among all tested samples are nearly the same. Red bars indicate abnormal values. Blue boxes, the bottom and top of the box are the first and third quartiles, and the band inside the box is the median. (b) The scatter plot for assessing the lncRNA expression variation between cancer and para-cancer tissues. The values of X and Y axes in the scatter plot are the normalized signal values of the samples (log2 scaled) or the averaged normalized signal values of groups of samples (log2 scaled). The green lines are fold change lines (the default fold change value given is 1.5). The lncRNAs above the top green line and below the bottom green line indicated 41.5-fold change of lncRNAs between the two compared samples or the two compared groups of samples. (c) Hierarchical clustering for ‘differentially expressed lncRNAs for cancer versus para-cancer’. ‘Red’ indicates high relative expression, and ‘blue’ indicates low relative expression. The result from hierarchical clustering shows a distinguishable lncRNA expression profiling among samples. (d) qPCR detection showed all breast cancer cell lines bear higher expression level of APOC1P1-3 than non-tumoral mammary epithelial cell line MCF10A. Data are shown as the mean ± S.D. Error bars indicate S.D. **P<0.01 versus control (MCF10A). (e) qPCR detection in 25 pairs of fresh tissues showed APOC1P1-3 was highly expressed in breast cancer tissues. \[\Delta\Delta Ct = \Delta Ct (cancer) - \Delta Ct (normal), \Delta Ct = Ct (APOC1P1-3) - Ct (GAPDH)\]
decreased in breast cancer tissues (fold change ≥ 1.5, Supplementary Table S4). Hierarchical clustering showed systematic variations in expression of lncRNAs in normal versus cancer tissues (Figures 1a–c). We found that lincRNA-APOC1P1-3 (fold change = 2.02, P-value = 0.02, and full length = 631 bp) met the selection criteria and then was taken into further validation. To investigate the role of APOC1P1-3, we compared its expression profiles in cultured cells (MCF10A versus BT549, MCF7, MDA-MB-231, MDA-MB-453, MDA-MB-468, MCF7/Adr, and T47D) and 25 pairs fresh tissues (cancer versus matched normal tissues) with qPCR. Again, our data showed lincRNA-APOC1P1-3 was overexpressed in both breast cancer cell lines and tissues (Figures 1d and e).

Hypomethylation in APOC1P1 promoter region. Methylation of gene promoter has been proved to be eventful in gene epigenetic regulation. To determine whether methylation modifications exist in APOC1P1 gene promoter region, we quantified C/G methylation levels in the first exon of APOC1P1 with its upstream 1000-bp region using pyrosequencing in 3 normal and 10 breast tissues to quantify the degree of methylation at each CG site. All 16 C/G sites of the designated region were subjected to pyrosequencing. The pyrosequencing results showed that one of the 16 C/G methylation sites was significantly hypomethylated in breast cancer tissues when compared with normal tissues (Figure 2), whereas the other fifteen sites showed no differences. These results indicate that the hypomethylation of the C/G site may contribute to the upregulation of APOC1P1 in breast cancer.

LincRNA-APOC1P1-3 is related to the tumor size. To characterize the role of APOC1P1-3 overexpression in breast cancers, we examined the relationship between expression of APOC1P1-3 and clinicopathologic parameters (age, molecular subtypes (luminal A like, luminal B like, HER2 positive, and triple negative), breast cancer biomarkers (estrogen receptor (ER), progesterone receptor (PgR), and HER2), lymph node status, distant metastasis, and pTNM stage). We found that APOC1P1-3 expression was positively associated with tumor size (P = 0.0142). Tumors with a larger volume (≥2.5 cm) tended to exhibit higher APOC1P1-3 expression. However, there was no significant relationship between APOC1P1-3 expression and other parameters (Table 1).

LincRNA-APOC1P1-3 regulates early apoptosis in breast cancer cells. To determine the biological function of lincRNA-APOC1P1-3, we performed gain/loss function studies. We found that MCF7 and MDA-MB-231 cells can be effectively upregulated and downregulated by pcDNA3.1 and siRNA transfection, respectively (Figure 3a). The CCK8 proliferation assay showed that viable cells in siRNA/Control
Table 1 Relationship between APOC1P1-3 expressions in cancer tissues and clinicopathologic parameters (n = 90)

|                        | n   | APOC1P1-3 expression | P-value |
|------------------------|-----|----------------------|---------|
|                        |     | High | Low |       |
| **Menopause**          |     |      |     |       |
| No                     | 41  | 21   | 20  | 0.8324 |
| Yes                    | 49  | 24   | 25  |       |
| **Tumor size (cm)**    |     |      |     |       |
| ≥ 2.5                  | 22  | 16   | 6   | 0.0142 |
| < 2.5                  | 68  | 29   | 39  |       |
| **Distant metastasis** |     |      |     |       |
| Yes                    | 10  | 6    | 4   | 0.5023 |
| No                     | 80  | 39   | 41  |       |
| **Lymph node metastasis** |    |      |     |       |
| Yes                    | 42  | 24   | 18  | 0.2049 |
| No                     | 48  | 21   | 27  |       |
| **Nottingham grade**   |     |      |     |       |
| Grade I                | 24  | 12   | 12  | 0.5923 |
| Grade II               | 42  | 23   | 19  |       |
| Grade III              | 24  | 10   | 14  |       |
| **St Gallen subtype**  |     |      |     |       |
| Luminal A              | 29  | 17   | 12  | 0.5257 |
| Luminal B              | 29  | 12   | 17  |       |
| HER2 positive          | 18  | 8    | 10  |       |
| Basal like             | 14  | 8    | 6   |       |
| **ER**                 |     |      |     |       |
| ≥ 1%                   | 57  | 28   | 29  | 0.8269 |
| < 1%                   | 33  | 17   | 16  |       |
| **PgR**                |     |      |     |       |
| ≥ 1%                   | 49  | 24   | 25  | 0.8324 |
| < 1%                   | 41  | 21   | 20  |       |
| **HER2**               |     |      |     |       |
| Overexpression         | 35  | 19   | 16  | 0.5165 |
| Negative               | 55  | 26   | 29  |       |
| **ki67**               |     |      |     |       |
| ≥ 20%                  | 66  | 35   | 31  | 0.3404 |
| < 20%                  | 24  | 10   | 14  |       |

*The cutoff value is the median expression level of APOC1P1-3 (the value ≥ 0.1856 is considered high expression)

The APOC1P1-3 expression is related to the tumor size

HER2 status was validated by fluorescence in situ hybridization

Discussion

Identification of IncRNA is one of the most significant discoveries in contemporary science. LncRNAs have an essential role in epigenetics, transcriptional regulation, growth and development, and constitute part of the nucleus. LncRNAs also function in tumor cell proliferation, apoptosis, invasion, and metastasis. In current studies, we found lncRNA-APOC1P1-3 was overexpressed in breast cancer and the promoter region was hypomethylated. APOC1P1-3 could bind to α-tubulin and affect its acetylation, leading to cell apoptosis inhibition. On the basis of these findings, we propose a regulatory mechanism for APOC1P1-3 in breast cancer (Figure 6).

Methylation of gene promoter is important in gene epigenetic regulation. Hypomethylation of IncRNA has been found in cancers. Some breast cancer related genes, such as BRCA1, are known to be regulated by methylation modification. Recently, the methylation of IncRNA was also reported. As expression of APOC1P1-3 is high in breast cancer, using pyrosequencing to detect the CpG methylation levels, we examined whether the promoter region was hypomethylated. Cross talk occurs between IncRNAs and methylation regulatory network. Presence of CpG island demethylation in the IncRNA promoter leads to overexpression of IncRNA transcription. Our study suggests that the hypomethylation of IncRNA promoter regulates expression of IncRNA. We have predicted binding proteins of the hypomethylation region using AliBaba 2.1, which suggests transcription factor Sp1 is a potential binding protein (Figure 7). In view of the important regulatory role of Sp1 in gene expression, we consider overexpression of APOC1P1-3 may be due to the promoter hypomethylation followed by Sp1 activation. Further investigation on involvements of histone demethylases and Sp1 is needed.
Figure 3  APOC1P1-3 can affect apoptosis of breast cancer cells. (a) qPCR to detect transfection efficiency. (b–d) After transfection for 24 h, CCK8 assay and flow cytometry were carried out to detect cell proliferation (b), early apoptosis (c), and cell cycle (d). MCF7 cells were cultured in serum-free medium. Data are shown as the mean ± S.D. based on at least three independent experiments. Error bars indicate S.D. *P < 0.05 versus control; **P < 0.01 versus control; NS, no significant versus control.
LncRNAs affect tumor proliferation via cell cycle and apoptosis. Caspase-3 is the main executor of apoptosis. Expression levels of cleaved caspase-3 reflect caspase-3 activities and degrees of apoptosis. Thus, we assessed early apoptosis and caspase-3 activation (CCK8 assay, flow cytometry, and western blot analysis) during APOC1P1-3 silencing and overexpression. We found that APOC1P1-3 repressed apoptosis of breast cancer to facilitate its proliferation through altering the apoptotic protein levels. These results support that APOC1P1-3 regulates the breast cancer development by regulating apoptosis.

In spite of the complexity and diversity of mechanisms, most studies report that lncRNAs exert effects by directly binding to chromatin modification complexes (HOTAIR, Xist, and Tsil) or non-chromatin modification proteins (Dreh). We used an RNA pull-down assay to identify binding proteins. Mass spectrometry, western blots, and RIP identified tubulin as a specific binding protein. Tubulin is the major constituent of microtubules and cytoskeletal structure, and has critical role in cell mitosis and chromosome segregation, as well as cell proliferation and migration. Post-translational modifications of α- and β-tubulin are key in regulation. α-Tubulin acetylation (transfer of the acetyl group from acetyl-coenzyme A to Lys-40) regulates the structure and function of microtubules. Inhibition of tubulin polymerization and increased acetylation of α-tubulin contribute to cancer cell apoptosis. We found that APOC1P1-3 bound to tubulin, and APOC1P1-3 overexpression decreased α-tubulin acetylation, suggesting that tubulin may be a target of APOC1P1-3. However, the effects of APOC1P1-3 on acetylation of α-tubulin remains unknown.

Apolipoprotein C-1 (APOC1) protein is highly expressed in pancreatic cancer. It stimulates cell proliferation and prevents cell apoptosis. However, APOC1 protein was found to be downregulated in breast cancer patients. APOC1P1 is the pseudogene of APOC1. Generally, the antisense transcripts produced from pseudogenes can hybridize to corresponding mRNAs, forming dsRNAs cleaved by Dicer to endogenous siRNAs. Our findings provide an explanation for low expression levels of APOC1 in breast cancer patients. Further study is clearly needed to investigate the interaction between the two genes.

In summary, our study demonstrates that lncRNA-APOC1P1-3 is overexpressed in breast cancer, and its upregulation promotes cell proliferation by suppressing cell apoptosis. APOC1P1-3 can bind to tubulin, and then increase α-tubulin acetylation and inhibit apoptosis. In addition, the promoter region of APOC1P1 is hypomethylated, which contributes to the transcription activation and APOC1P1-3 overexpression. We conclude that lncRNA-APOC1P1-3 is involved in the breast cancer development.

Materials and Methods

The information for tumor tissues, cell lines, PCR, western blot, immunohistochemistry, proliferation assay, and cell cycle assay were provided in the Supplementary Materials.

LncRNA expression microarray analysis. Five matched breast cancer and normal tissues were used for microarray (Table S1). Total RNA was extracted using TRizol (Ambion, Carlsbad, CA, USA), and transcribed into cDNA using Quick Amp Labeling kit (Agilent, Palo Alto, CA, USA). After hybridization, using Human LncRNA Microarray v2.0 (Arraystar, Rockville, MD, USA), slides were scanned with the Agilent DNA Microarray Scanner (Agilent p/n G2563BA) and analyzed with Agilent Feature Extraction software v. 11.5.1.1. Quantile normalization and subsequent data processing were performed using the Agilent GeneSpring GX v11.5.1. Differentially expressed lncRNAs with statistical significance were identified through volcano plot filtering (threshold: P-value < 0.05, fold change ≥ 1.5, and false discovery rate ≤ 0.05). Microarray array data analysis was completed by Shanghai KangChen bio-tech (Shanghai, China).
candidate lncRNAs should meet the following criteria: (1) RNA length < 3 kb; (2) negative X-hybridization (cross-hybridization) result: the probe can not be hybridized with other lncRNAs or mRNAs; (3) sequences do not overlap with nearby mRNAs; (4) P-value, as small as possible; fold change, as big as possible; and raw intensity, as high as possible; and (5) comparable with the latest version of the relative database (NCBI Reference Sequence, UCSC Knowngenes, and Ensembl Genome).

Pyrosequencing. The pyrosequencing work was accomplished by the cpgbiotech company (Shanghai, China). Three normal breast tissues and 10 breast cancer tissues were obtained from Huashan Hospital, Fudan University. Primers were designed by PyroMark Assay Design Software 2.0 (Qiagen, Hilden, Germany). Amplification primers sequences (in 5′ – 3′ orientation) and the sequencing primers are listed in the Supplementary Table S2. One of the primers must be biotinylated, which enables conversion of the PCR product to a single-stranded DNA template for pyrosequencing. The technological processes were: (1) bisulfite treatment and elution of genomic DNA (C → U and mC → mC; Qiagen); (2) PCR amplification (U → T and mC → C; PyroMark PCR kit, Qiagen, Hilden, Germany). Both methylated and unmethylated DNA sequences of the designated regions were amplified with its specific primers; (3) streptavidin-coated beads separated specific PCR products into single strand; (4) sequencing primer was complementary to the single-stranded DNA.
added, which annealed to a fixed single-stranded DNA template; and (5) quantitative methylation detection by pyrosequencing was completed with Biotage PyroMark Q24 system (Qiagen, Hilden, Germany) according to manufacturer’s instructions, and data were analyzed with Pyromark software (Qiagen). Calculation of C:T peaks represent the methylation.6

Plasmid and siRNA transfection. The cDNA encoded full-length lincRNA-APOC1P1-3 was PCR-amplified using primers (5'-CAACGAGGCTCCAGCAAGC-3' and 5'-GGCTCGAGGCTCCAGGATAG-3'), amplification was performed for 35 cycles at 95°C for 45 s, at 65°C for 45 s, and at 72°C for 1 min, and subcorded into Bam H1 and Xho I sites of a pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA), named pcDNA3.1/APOC1P1-3. Transfections for pcDNA3.1/APOC1P1-3 and siRNA/APOC1P1-3 (Supplementary Table S3) were performed using the lipofectamine-2000 (Invitrogen) with Opti-MEM (Gibco, Grand Island, NY, USA) according to the manufacturer’s instructions. Total RNA and protein were collected after 24 and 48 h, respectively.

Apoptosis detection. Flow cytometry was used to detect the apoptotic cells. After transfection with lipofectamine 2000 and Opti-MEM for 6 h, cells were maintained in fresh medium supplemented with 1% FBS for 24 h. Thereafter, cells were collected and washed with phosphate-buffered saline. Finally, cell apoptosis was detected by flow cytometry (BD Bioscience, Franklin Lakes, NJ, USA) after incubation with annexin V-FITC and propidium iodide for 15 min. Data were acquired with a BD FACsVerse system and BD FACSsuite software. (San Jose, CA, USA)

RNA pull-down. Biotin-labeled, full-length APOC1P1-3 RNA and antisense APOC1P1-3 were prepared with Biotin RNA Labeling Mix (Roche, Indianapolis, IN, USA) and T7 RNA polymerase (Roche). Biotinylated RNAs were treated with RNase-free DNase I (Roche) and purified with the RNeasy Mini kit (Qiagen, Valencia, CA, USA). Cell proteins were extracted with the ProteoJETTM Cytoplasmic and Nuclear Protein Extraction kit (Fermentas, St. Leon-Rot, Germany), and then mixed with Protein Extraction kit (Fermentas, St. Leon-Rot, Germany), and then mixed with biotin-labeled RNAs. Washed streptavidin agarose beads (Invitrogen) were added to each binding reaction, incubated at room temperature for 1 h, washed five times and boiled in SDS buffer. Retrieved protein was detected by SDS gel electrophoresis.

RNA immunoprecipitation. The RIP test was performed with the Magna RIP RNA-Binding Protein Immunoprecipitation kit (Millipore, Bedford, MA, USA) and α-tubulin (cat.# 2144, Cell Signaling Technology, Beverly, MA, USA) according to manufacturer’s instructions. In brief, beads were mixed with tubulin antibody or IgG and cell lysate, and rotated at room temperature for 4 h. The co-precipitated RNAs were detected by RT-PCR. Total RNAs (input controls) and isotype controls were assayed simultaneously to demonstrate that detected signals were from RNAs, specifically bound to α-tubulin.

Statistical analysis. Data were analyzed using SPSS 17.0 (Chicago, IL, USA). For comparisons, one-way analyses of variance, Fisher’s exact tests, χ²-tests, and two-tailed student’s t-tests were performed. P<0.05 was considered to be statistically significant. The diagrams were completed with Prism 5.0 (GraphPad Software, La Jolla, CA, USA).

Conflict of Interest. The authors declare no conflict of interest.

Acknowledgements. This research was supported by grants from the Natural Science Foundation of China (81372849, 81172507, 81272387, and 81470857), Shanghai Municipal Commission of Health (2012-433) and Natural Science Foundation of Science and Technology Committee of Shanghai Municipality (16ZR1403300).

LincRNA-APOC1P1-3 in breast cancer

XH Liao et al

Figure 7 Transcription factor Sp1 is a potential binding protein of the hypomethylation region of APOC1P1. AllBaba 2.1 (http://www.gene-regulation.com/pub/programs/alibaba2/index.html) was used to predict the binding proteins. The promoter sequence and the binding segments of Sp1 are shown
inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology 2013; 57: 1882–1892.

23. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000; 69: 277–302.

24. Janke C. The tubulin code: molecular components, readout mechanisms, and functions. J Cell Biol 2014; 206: 461–472.

25. Wloka D, Gaertig J. Post-translational modifications of microtubules. J Cell Sci 2010; 123: 3447–3455.

26. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003; 4: 938–947.

27. Li L, Yang XJ. Tubulin acetylation: responsible enzymes, biological functions and human diseases. Cell Mol Life Sci 2015; 72: 4237–4255.

28. Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F et al. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene 2008; 27: 2810–2822.

29. Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J et al. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol 2010; 136: 1243–1254.

30. Vikram R, Ramachandran R, Abdul KS. Functional significance of long non-coding RNAs in breast cancer. Breast Cancer 2014; 21: 515–521.